Skip to content

Cervical Medial Branch Block Versus Ipsilateral Cervical Erector Spinae Plane Block

Ultrasound-Guided Cervical Medial Branch Block Versus Ipsilateral Cervical Erector Spinae Plane Block in Cervical Facetogenic Pain: A Prospective Randomized Controlled Study

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07595406
Acronym
CERVESP
Enrollment
130
Registered
2026-05-19
Start date
2026-05-31
Completion date
2026-12-31
Last updated
2026-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Facet Joint Syndrome, Cervical Facetogenic Pain, Chronic Neck Pain

Brief summary

This prospective randomized controlled study aims to compare the analgesic effectiveness of ultrasound-guided cervical medial branch block and ipsilateral cervical erector spinae plane block in patients with cervical facetogenic pain. Patients with chronic cervical facet-mediated pain will be randomized into two intervention groups. Pain intensity, functional status, meaningful pain response rates, analgesic consumption, and patient satisfaction will be evaluated during follow-up. The primary objective is to determine whether cervical erector spinae plane block provides comparable short-term pain relief to cervical medial branch block.

Detailed description

Cervical facet joints are an important source of chronic axial neck pain. Diagnostic cervical medial branch block is commonly used to identify facet-mediated pain and may also provide short-term analgesic benefit. However, this procedure requires precise targeting of the cervical medial branches and may be technically demanding in some patients. The cervical erector spinae plane block is an ultrasound-guided interfascial plane block that may provide analgesia through cranio-caudal spread of local anesthetic along the paraspinal fascial plane. Although it has been increasingly used for perioperative and chronic pain indications, its role in cervical facetogenic pain has not been clearly established. This study will compare the short-term analgesic effectiveness of ultrasound-guided cervical medial branch block and ipsilateral cervical erector spinae plane block in patients with clinically suspected cervical facetogenic pain. Eligible patients will be randomized to receive one of the two ultrasound-guided interventions. Pain intensity, functional disability, meaningful pain response, analgesic use, patient satisfaction, and procedure-related adverse events will be assessed during follow-up. The study is designed to determine whether cervical erector spinae plane block can provide clinically meaningful pain relief comparable to cervical medial branch block in this patient population.

Interventions

OTHERUltrasound-guided cervical medial branch block

Ultrasound-guided cervical medial branch block performed at clinically suspected symptomatic cervical facet levels using local anesthetic for diagnostic and analgesic purposes.

OTHERUltrasound-guided cervical erector spinae plane block

Ultrasound-guided ipsilateral cervical erector spinae plane block performed at the symptomatic cervical level using local anesthetic for analgesic purposes.

Sponsors

Ankara City Hospital Bilkent
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

Participants will be blinded to treatment allocation. Due to the technical and procedural differences between the interventions, the physician performing the procedure cannot be blinded.

Intervention model description

Participants with clinically suspected cervical facetogenic pain will be randomly assigned in a parallel-group design to receive either ultrasound-guided cervical medial branch block or ultrasound-guided ipsilateral cervical erector spinae plane block. Outcomes including pain intensity, meaningful pain response, functional status, analgesic consumption, and patient satisfaction will be compared between the two intervention groups during follow-up.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age between 18 and 80 years * Chronic neck pain lasting at least 3 months * Clinical findings suggestive of cervical facetogenic pain * Numeric Rating Scale pain score ≥4 * Ability to provide informed consent

Exclusion criteria

* Cervical radiculopathy or myelopathy * Major neurological deficit * Infection at the injection site * Coagulopathy or anticoagulant therapy contraindicating intervention * Allergy to local anesthetics * Pregnancy * Previous cervical interventional pain procedure within the last 3 months * Severe psychiatric disease

Design outcomes

Primary

MeasureTime frameDescription
Meaningful Pain ResponseTime Frame: 1 hour after the procedureProportion of patients achieving at least 50% reduction in Numeric Rating Scale (NRS) pain score during the early post-procedural period.

Secondary

MeasureTime frameDescription
NRS24at 24 HoursChange in pain intensity measured using the 11-point Numeric Rating Scale (0=no pain, 10=worst imaginable pain).
NRS11 week after the procedureChange in pain intensity measured using the 11-point Numeric Rating Scale.( 0=no pain, 10=worst imaginable pain)
NDIBaseline and 1 week after the procedureFunctional disability associated with neck pain assessed using the Neck Disability Index.0 = no disability 50 = complete disability Higher scores indicate greater neck-related functional disability (worse outcome).
GPE1 week after the procedurePatient-reported global improvement evaluated using a 7-point Global Perceived Effect scale. The GPE scale ranges from -5 to +5, where: -5 = vastly worse 0 = no change +5 = completely recovered
Analgesic Consumption24 hours and 1 week after the procedureNeed for rescue analgesic medication after the procedure.
Patient Satisfaction1 week after the procedurePatient satisfaction regarding the procedure.
ComplicationsPerioperative/PeriproceduralProcedure-related adverse events and complications.

Countries

Turkey (Türkiye)

Contacts

CONTACTÜlkü Sabuncu, Assoc prof
sabuncuulku@gmail.com905337085212

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 20, 2026